TargetBeta
IL1B
interleukin 1 beta · also IL1F2, IL-1B, IL1-BETA · Interleukins
4 programs in company-led studies act on IL1B, from 3 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| diacereinrule | Castle Creek Pharmaceuticals | phase 4 | 212 running | – | the studies' text |
| lutikizumab | AbbVie | phase 3 | 128 running | IL1A | the company's pipeline |
| arumakimig | Novartis | phase 2 | 73 running | IL18 | the company's pipeline |
| ABBV-1451 | AbbVie | phase 1 | 11 running | IL1A | the company's pipeline |
Conditions their studies are in
- Hidradenitis Suppurativa, 2 programs
- Arthritis, 1 program
- Arthritis, Juvenile, 1 program
- Arthritis, Psoriatic, 1 program
- Arthritis, Rheumatoid, 1 program
- Coronary Disease, 1 program
- Crohn Disease, 1 program
- Enterocolitis, 1 program
- Epidermolysis Bullosa, 1 program
- Epidermolysis Bullosa Simplex, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026lutikizumab · AbbVie · phase 3 · NCT06468228
- Dec 31, 2026diacerein · Castle Creek Pharmaceuticals · phase 4 · NCT04318041
- Apr 2027ABBV-1451 · AbbVie · phase 1 · NCT07570147
- Apr 22, 2027arumakimig · Novartis · phase 2 · NCT07203001
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.